Timothy J Carroll
University of Chicago, IL·Biomedical Engineering
During an ischemic stroke, a blocked blood vessel cuts off oxygen to part of the brain. Neurons then die at an estimated rate of about one million per minute, so treatment must be fast.
- Fields
Biomedical Engineering
Medicine & Clinical Research
Neuroscience
- Topics
acute ischemic stroke
infarct growth
cerebral infarction
- Grants
- 1 known grant, through Jul 2030
What they work on
- Test whether Sanguinate®, a pegylated bovine hemoglobin blood substitute bound to carbon monoxide, boosts leptomeningeal collateral blood flow and reduces infarct volume and growth in a controlled model of ischemic stroke.
- Compare doses and time-to-treatment of Sanguinate using serial imaging of tissue perfusion, infarct growth and tissue hypoxia, to find out how dosing and timing change its protective effect.
- Determine whether Sanguinate reduces reperfusion injury, the damage that occurs when blood flow returns after recanalization, using biomarkers of brain damage and inflammation alongside imaging.
- Clarify Sanguinate's mechanism of action in delivering oxygen to low-oxygen ischemic tissue, to inform the design of future human clinical trials.
More about the research
The team has previously shown that how fast the damaged area, called the infarct, grows varies widely between patients. That speed depends strongly on leptomeningeal collaterals, the backup blood vessels on the brain's surface that can reroute blood flow. Even with the fastest care, millions of neurons die before the clot is cleared. There is therefore a need for a safe intravenous treatment that could be given to every stroke patient as soon as symptoms appear. Clot-busting drugs cannot fill this role because they are not safe for all patients.
Why it matters
Patients with acute ischemic stroke lose brain tissue every minute before the blocked vessel is reopened. An easy intravenous oxygen-carrying treatment that could be given in ambulances, emergency rooms or smaller hospitals before transfer to a stroke center might slow infarct growth and reduce reperfusion injury. This could limit long-term disability. The findings are intended to shape future human clinical trials of the agent.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Kaveh Laksari
University of California-Riverside, CA·Biomedical Engineering
Develop and validate a fully automatic algorithm that extracts brain-vessel shape and geometry from MR and CT angiograms of acute ischemic stroke patients in real time.
Radhika Muzumdar
University of Pittsburgh, PA·Physiology
Determine how effectively humanin, a small peptide encoded in mitochondria, protects the heart in mouse models of myocardial ischemia-reperfusion injury and ischemia-induced heart failure in aging, measuring infarct size and cardiac function.
James Ross
Case Western Reserve University, OH·Medicine & Clinical Research·Early-career
Define how free hemoglobin lowers nitric oxide availability and triggers endothelial injury in human endothelial cell models, and test whether haptoglobin, a hemoglobin-binding protein, reduces these effects.
The school
University of Chicago: 39 labs on PI Pages, $681M a year on research, 457 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.